flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 In the trial, researchers assessed whether the glucagon-like peptide 1 receptor agonist was effective in preventing progression of disease in patients with type 2 diabetes and chronic kidney disease Can Ozempic protect your kidneys

Holliday, A

The obvious conclusion of these findings is that we should view obesity as a medical condition, like high blood pressure, where effective and safe drug therapy can contribute to reducing serious adverse health outcomes. Novo Nordisk expects to file for regulatory approvals to expand the use of the drug to protect against major adverse cardiovascular events in the US and the EU later this year

Potential risks require ongoing research, and regular medical guidance is essential to monitor health impacts

All thats missing is the Big Pharma funding, which you and I know will never arrive

Here is a framework for narrowing the options

Trends Mol Med 27:895906 Kovarik JJ, Bileck A, Hagn G, Meier-Menches SM, Frey T, Kaempf A, Hollenstein M, Shoumariyeh T, Skos L, Reiter B, Gerner MC, Spannbauer A, Hasimbegovic E, Schmidl D, Garhofer G, Gyongyosi M, Schmetterer KG, Gerner C (2023) A multi-omics based anti-inflammatory immune signature characterizes long Covid-19 syndrome